Knockdown of ACAT-1 reduces amyloidogenic processing of APP

Neurobiology of Disease Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, United States.
FEBS Letters (Impact Factor: 3.17). 05/2007; 581(8):1688-92. DOI: 10.1016/j.febslet.2007.03.056
Source: PubMed


Previous studies have shown that acyl-coenzyme A:cholesterol acyl transferase (ACAT), an enzyme that controls cellular equilibrium between free cholesterol and cholesteryl esters, modulates proteolytic processing of APP in cell-based and animal models of Alzheimer's disease. Here we report that ACAT-1 RNAi reduced cellular ACAT-1 protein by approximately 50% and cholesteryl ester levels by 22% while causing a slight increase in the free cholesterol content of ER membranes. This correlated with reduced proteolytic processing of APP and 40% decrease in Abeta secretion. These data show that even a modest decrease in ACAT activity can have robust suppressive effects on Abeta generation.

Download full-text


Available from: Dora M Kovacs, Oct 03, 2015
20 Reads
  • Source
    • "Some other enzymes may also be involved with Aâ, such as acyl-coenzyme A cholesterol acyltransferase (ACAT-1), an enzyme that controls cellular equilibrium between free cholesterol and cholesteryl ester and modulates the proteolytic processing of APP in cell-based and animal models of AD.58,59 ACAT-1 RNAi, through a single transfection of ACAT-1 siRNA oligonucleotides, reduces cellular ACAT-1 protein by ~50%, cholesteryl ester levels by 22%, and causes a slight increase in the free cholesterol content of ER membranes, which correlates with reduced proteolytic processing of APP and a 40% decrease in Aâ secretion.60 In addition, endogenous ferritin knockdown by RNAi can decrease iron in mammal cell cultures and promote the formation of well-ordered aggregates of Aâ while decreasing its toxicity.61 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized clinically by memory and cognitive dysfunction. Unfortunately, there is no effective therapeutic method for AD treatment or ways to halt disease progression. Many mechanisms are involved in the disease, including genes mutation and protein dysfunction. RNA interference (RNAi) technology may potentially be able to control AD. It can inhibit the protein expression of specific genes by activating a sequence-specific RNA degradation process. This is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we highlight the advances in RNAi technology in the investigation and treatment of AD.
    Drug Design, Development and Therapy 02/2013; 7:117-25. DOI:10.2147/DDDT.S40229 · 3.03 Impact Factor
  • Source
    • "Full-length APP protein levels were analyzed using a carboxyl-terminal-directed antibody that recognizes the carboxyl terminal fragments (CTFs) and the full-length APP holoproteins (mature APP or mAPP and immature APP or imAPP). The binding capacity of the antibody has been confirmed in previous studies [41]–[43]. WB showed a remarkable reduction in both mature and immature APP holoprotein levels in central Ang II-treated animals: about a 50% reduction with low-dose and medium-dose Ang II (p<0.01), and about a 70% reduction with high-dose Ang II (p<0.01), relative to saline-treated controls (Figure2A and Figure2C). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stress and various stress hormones, including catecholamines and glucocorticoids, have recently been implicated in the pathogenesis of Alzheimer's disease (AD), which represents the greatest unresolved medical challenge in neurology. Angiotensin receptor blockers have shown benefits in AD and prone-to-AD animals. However, the mechanisms responsible for their efficacy remain unknown, and no studies have directly addressed the role of central angiotensin II (Ang II), a fundamental stress hormone, in the pathogenesis of AD. The present study focused on the role of central Ang II in amyloidogenesis, the critical process in AD neuropathology, and aimed to provide direct evidence for the role of this stress hormone in the pathogenesis of AD. Increased central Ang II levels during stress response were modeled by intracerebroventricular (ICV) administration of graded doses of Ang II (6 ng/hr low dose, 60 ng/hr medium dose, and 600 ng/hr high dose, all delivered at a rate of 0.25 µl/hr) to male Sprague Dawley rats (280-310 g) via osmotic pumps. After 1 week of continuous Ang II infusion, the stimulation of Ang II type 1 receptors was accompanied by the modulation of amyloid precursor protein, α-, β-and γ-secretase, and increased β amyloid production. These effects could be completely abolished by concomitant ICV infusion of losartan, indicating that central Ang II played a causative role in these alterations. Central Ang II is essential to the stress response, and the results of this study suggest that increased central Ang II levels play an important role in amyloidogenesis during stress, and that central Ang II-directed stress prevention and treatment might represent a novel anti-AD strategy.
    PLoS ONE 01/2011; 6(1):e16037. DOI:10.1371/journal.pone.0016037 · 3.23 Impact Factor
  • Source
    • " with an ACAT inhibitor ( CP - 113818 ) causes a decrease in brain CE and amyloid pathology , and results in a significant improvement in spatial learning ( Hutter - Paier et al . 2004 ) . ACAT - 1 - specific RNAi knockdown has also been shown to reduce amyloidogenic processing of APP , causing a reduction in Ab secretion from treated cell lines ( Huttunen et al . 2007 ) . ACAT inhibitors have been widely studied for the treatment of atherosclerosis , they reduce plasma apoB containing lipoproteins and suppress intestinal apoB48 synthesisl ; therefore , chylomicron cholesterol and TAG absorption is decreased ( Leon et al . 2005 ) . In the liver , ACAT inhibitors inhibit the secretion of apoB100 and as"
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most common neurodegenerative disorder, affecting millions of people worldwide. Apart from age, the major risk factor identified so far for the sporadic form of AD is possession of the epsilon4 allele of apolipoprotein E (APOE), which is also a risk factor for coronary artery disease (CAD). Other apolipoproteins known to play an important role in CAD such as apolipoprotein B are now gaining attention for their role in AD as well. AD and CAD share other risk factors, such as altered cholesterol levels, particularly high levels of low density lipoproteins together with low levels of high density lipoproteins. Statins--drugs that have been used to lower cholesterol levels in CAD, have been shown to protect against AD, although the protective mechanism(s) involved are still under debate. Enzymatic production of the beta amyloid peptide, the peptide thought to play a major role in AD pathogenesis, is affected by membrane cholesterol levels. In addition, polymorphisms in several proteins and enzymes involved in cholesterol and lipoprotein transport and metabolism have been linked to risk of AD. Taken together, these findings provide strong evidence that changes in cholesterol metabolism are intimately involved in AD pathogenic processes. This paper reviews cholesterol metabolism and transport, as well as those aspects of cholesterol metabolism that have been linked with AD.
    Journal of Neurochemistry 12/2009; 111(6):1275-308. DOI:10.1111/j.1471-4159.2009.06408.x · 4.28 Impact Factor
Show more